Purchase this article with an account.
HE HUI, Shangkun Ou, Liying zhang, Juan Li, Zuguo Liu, Wei Li; The effect of mesenchymal stem cells on corneal wound healing after chemical injury: A case serials clinical study.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4102. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Previous studies have demonstrated that mesenchymal stem cells (MSCs) is beneficial for ocular surface wound healing after chemical injury on animal model. The aim of current study was to investigate the efficacy of MSCs on corneal wound healing in clinical setting.
Six patients who were diagnosed as ocular surface chemical injury were enrolled in this study under approval of Ethical committee of Xiamen Eye Center. Human umbilical cord MSCs (UC-MSCs) were cultured from umbilical cord of a donated placenta and expanded under standardized protocol. A total of 4×106 cells of passage 4 were injected in the subconjunctival stroma close to superior and inferior limbal region. Simultaneously, amniotic membrane transplantation was performed and TobraDex eye drops, TobraDex eye gel, recombinant human epidermal growth factor eye drops, and Solcoseryl eye drops were applied for 4 weeks. The slit lamp microscopy examination and fluorescein staining was performed at follow-up.
All the patients showed conjunctival edema and congestion, limbal ischemia, and corneal epithelial defect before treatment. Anterior uveitis and corneal ulceration were not observed in all patients. Four weeks after cell injection, limbal ischemia diminished in 5 patients and dramatically reduced in one patient. Conjunctival edema and congestion was reduced in all the patients. The corneal epithelial defect was healed in 5 out of 6 patients, and partially healed in one patient. No systemic side effect such as fever or hemorrhagic tendency was found after MSCs injection in all patients.
Our clinical observation demonstrated the feasibility of MSCs in the treatment of chemical injuries of the ocular surface. One dose application of MSCs may improve clinical outcome through reducing inflammation and promoting corneal re-epithelization.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only